Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

WCLC 2024 Insights: Optimal Management of Malignant Pleural Effusion

Insights from 2024 WCLC

P. Lee

ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-…

2024 ESMO Annual Meeting Insights Hub

K. Natsuhara

Neoadjuvant vs. Adjuvant: A New Paradigm for NSCLC

Total Health

D. Carbone

Role of Surgery in Locally Advanced NSCLC

Memorial Sloan Kettering Cancer Center

K. Gray

ELCC 2025 Summary: Monday Morning Practice - MARIPOSA Highlights & F…

Insights from ELCC 2025

B. Halmos

ESMO 2024 Summary: Key Trial Insights on Managing NSCLC With Low PD-…

ecancer

L. Paz-Ares

EGFRm Lung Cancer: Overview & Treatment Sequence

GRACE

J. Rotow

The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

IO Advances in Metastatic NSCLC Treatment

Fox Chase Cancer Center

H. Borghaei

Imaging of Precision Therapy in Lung Cancer

International Cancer Imaging Society (ICIS)

M. Nishino

FDA Approval of Zenocutuzumab for Advanced NRG1 Fusion-Positive NSCL…

Memorial Sloan Kettering Cancer Center

A. Schram

Lazertinib in 1L EGFR-Mutant NSCLC: Unique Mechanism and Benefits of…

Mariam Alexander

Metastatic EGFRm NSCLC: 1L Therapy Options

University of Colorado Cancer Center

T. Patil

An Update of ADC Toxicities in Solid Tumors

OncoAlert

M. Lustberg

Surveillance Imaging in Solid Tumors: More Complicated Than It Appea…

ecancer

C. Booth

Current Landscape of Neoadjuvant, Perioperative, and Adjuvant IO in …

UCLA Health

J. Lee

Unresectable Stage 3 NSCLC: Patient Selection and Treatment Options

Fox Chase Cancer Center

C. Aggarwal

Year in Review 2024 - Targeted Therapy for NSCLC

Nebraska Oncology Society

J. Murray

WCLC 2024 Review: MARIPOSA Trial - Extended Follow Up and Patient Re…

ecancer

E. Felip